Bowel Perforation after Erlotinib Treatment in a Patient with Non-Small Cell Lung Cancer
Yonsei Medical Journal
;
: 695-698, 2011.
Artículo
en Inglés
| WPRIM
| ID: wpr-33245
ABSTRACT
Erlotinib is accepted as a standard second-line chemotherapeutic agent in patients with non-small cell lung cancer who are refractory or resistant to first-line platinum-based chemotherapy. There has been no previous report of bowel perforation with or without gastrointestinal metastases related to erlotinib in patients with non-small cell lung cancer. The exact mechanism of bowel perforation in patients who received erlotinib remains unclear. In this report, we report the first case of enterocutaneous fistula in a female patient with metastatic non-small cell lung cancer 9 months, following medication with erlotinib as second-line chemotherapy.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Quinazolinas
/
Enfermedades del Sigmoide
/
Fístula Intestinal
/
Carcinoma de Pulmón de Células no Pequeñas
/
Inhibidores de Proteínas Quinasas
/
Perforación Intestinal
/
Antineoplásicos
Límite:
Anciano
/
Femenino
/
Humanos
Idioma:
Inglés
Revista:
Yonsei Medical Journal
Año:
2011
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS